Artivion (NYSE:AORT) Releases Earnings Results

Artivion (NYSE:AORT) issued its quarterly earnings results on Thursday. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.03, FiscalAI reports. Artivion had a positive return on equity of 5.98% and a negative net margin of 2.16%.The company had revenue of $118.30 million for the quarter, compared to analyst estimates of $116.42 million.

Artivion Trading Up 1.5%

Shares of Artivion stock traded up $0.61 during midday trading on Thursday, reaching $40.71. The company had a trading volume of 776,175 shares, compared to its average volume of 319,709. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.93 and a quick ratio of 2.88. Artivion has a fifty-two week low of $21.97 and a fifty-two week high of $48.25. The stock has a fifty day moving average price of $43.86 and a 200 day moving average price of $42.77. The firm has a market cap of $1.93 billion, a PE ratio of -169.63 and a beta of 1.59.

Insider Buying and Selling

In other news, CEO James P. Mackin sold 30,921 shares of the stock in a transaction on Tuesday, December 2nd. The shares were sold at an average price of $45.56, for a total transaction of $1,408,760.76. Following the completion of the sale, the chief executive officer directly owned 800,993 shares in the company, valued at $36,493,241.08. This represents a 3.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Marshall S. Stanton sold 47,376 shares of Artivion stock in a transaction on Friday, November 21st. The stock was sold at an average price of $45.04, for a total transaction of $2,133,815.04. Following the transaction, the senior vice president directly owned 44,753 shares of the company’s stock, valued at $2,015,675.12. This represents a 51.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 141,234 shares of company stock worth $6,366,621. Corporate insiders own 7.60% of the company’s stock.

Institutional Investors Weigh In On Artivion

Several large investors have recently added to or reduced their stakes in AORT. Dimensional Fund Advisors LP increased its holdings in Artivion by 0.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 980,837 shares of the company’s stock worth $44,737,000 after purchasing an additional 7,817 shares in the last quarter. AlphaCentric Advisors LLC acquired a new stake in shares of Artivion during the 4th quarter worth approximately $183,000. New York State Common Retirement Fund increased its stake in shares of Artivion by 0.8% in the 4th quarter. New York State Common Retirement Fund now owns 84,446 shares of the company’s stock valued at $3,852,000 after acquiring an additional 692 shares in the last quarter. Loomis Sayles & Co. L P boosted its stake in Artivion by 35.0% during the fourth quarter. Loomis Sayles & Co. L P now owns 840,062 shares of the company’s stock worth $38,315,000 after acquiring an additional 217,860 shares in the last quarter. Finally, Swiss National Bank raised its holdings in shares of Artivion by 12.4% during the fourth quarter. Swiss National Bank now owns 79,100 shares of the company’s stock valued at $3,608,000 after purchasing an additional 8,700 shares during the period. Institutional investors and hedge funds own 86.37% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on AORT. Needham & Company LLC reiterated a “buy” rating and issued a $58.00 target price on shares of Artivion in a research report on Monday, February 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artivion in a report on Wednesday, January 21st. Oppenheimer reissued an “outperform” rating and issued a $50.00 price objective on shares of Artivion in a research note on Friday, November 7th. Citizens Jmp raised their target price on shares of Artivion from $47.00 to $53.00 and gave the company a “market outperform” rating in a research report on Friday, November 7th. Finally, Wall Street Zen downgraded shares of Artivion from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 24th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $49.11.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.